A look at some of the latest renal and hepatic R&D
Brought to you byDDNews Staff
| 1 min read
Liver and kidney disease step into the spotlight at DDN
.
To continue reading this article, subscribe for FREE to
Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.
Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.
Here are some related topics that may interest you:
As long as DDN has been reporting on pharma and life-sciences research, a constant theme has been that cancer, the central nervous system, respiratory disease, and infectious disease tend to dominate the research realm—and thus much of our coverage. Less so liver and kidney disease, despite these organs being some of the hardest-working ones in the body.
After all, the liver breaks down harmful substances, then excretes its by-products into the bile or blood. Bile by-products enter the intestine and leave the body in the form of feces, while blood by-products are filtered out by the kidneys and leave the body in the form of urine.
In recent years, we’ve seen a sharp increase in liver-related topics in DDN, largely because of a surge in R&D related to non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Surprisingly, though, recent weeks have brought an influx of kidney-related stories, which we share here, along with some liver research news as well.
